SFPG
NRXP icon

Stonebridge Financial Planning Group’s NRX Pharmaceuticals NRXP Stock Holding History

Stonebridge Financial Planning Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8
Closed -$1K – 422
2021
Q2 		$1K Buy
+8
New +$2.11K ﹤0.01% 413

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Stonebridge Financial Planning Group's NRXP Position: Q3 2021 in Review

Stonebridge Financial Planning Group sold out of NRX Pharmaceuticals (NRXP) in Q3 2021, closing a stake of 8 shares — an estimated $1K sold.

Stonebridge Financial Planning Group first reported a position in NRXP in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 23 funds tracked by Wall St. Rank hold NRXP as of Q3 2021.

  • Stonebridge Financial Planning Group reported no remaining NRX Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Stonebridge Financial Planning Group sold 8 NRX Pharmaceuticals shares in Q3 2021, an estimated $1K.
  • Stonebridge Financial Planning Group first reported a position in NRX Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Stonebridge Financial Planning Group's NRX Pharmaceuticals position peaked at $1K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2021.

Based on Stonebridge Financial Planning Group's 13F filing for Q3 2021, filed 8 Nov 2021.